DESTIN, Fla. — Although patients with rheumatoid arthritis generally report satisfaction with their treatment, many remain “absolutely unsatisfied” with their disease state, according to Chinonso Akano, PharmD, of Eli Lilly.
“This study was done based on what patients are actually feeling, their perceptions and real-life experiences,” Akano told Healio Rheumatology. “It does show that about 26% are absolutely unsatisfied with the current therapies they are on.”
According to Akano, despite the many therapies for RA that are available, there remains a significant unmet need for RA patients in the real world.
“This really drives it home that regardless of all the therapies we have, the patients are still feeling unsatisfied with their disease state,” Akano said.
Disclosure: Akano reports being an employee and shareholder with Eli Lilly.